These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35121201)

  • 1. Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin.
    Liu J; Xie S; Shao X; Xue S; Du P; Wu H; Xu S; Chen ZS; Yang DH; Xu J; Yao H
    Eur J Med Chem; 2022 Mar; 231():114155. PubMed ID: 35121201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of Oridonin Derivatives via Mizoroki-Heck Reaction and Click Chemistry for Cytotoxic Activity.
    Hou W; Fan Q; Su L; Xu H
    Anticancer Agents Med Chem; 2019; 19(7):935-947. PubMed ID: 30657049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel oridonin analogues as potent anticancer agents.
    Shen QK; Chen ZA; Zhang HJ; Li JL; Liu CF; Gong GH; Quan ZS
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):324-333. PubMed ID: 29303372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway.
    Shen QK; Deng H; Wang SB; Tian YS; Quan ZS
    Eur J Med Chem; 2019 Jul; 173():15-31. PubMed ID: 30981113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies.
    Xu S; Wang G; Lin Y; Zhang Y; Pei L; Yao H; Hu M; Qiu Y; Huang Z; Zhang Y; Xu J
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2795-2800. PubMed ID: 27158140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.
    Xu S; Yao H; Luo S; Zhang YK; Yang DH; Li D; Wang G; Hu M; Qiu Y; Wu X; Yao H; Xie W; Chen ZS; Xu J
    J Med Chem; 2017 Feb; 60(4):1449-1468. PubMed ID: 28165738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents.
    Wang L; Li D; Xu S; Cai H; Yao H; Zhang Y; Jiang J; Xu J
    Eur J Med Chem; 2012 Jun; 52():242-50. PubMed ID: 22483090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spirolactone-type and enmein-type derivatives as potential anti-cancer agents derived from oridonin.
    Ni X; He C; Jia Y; Wu X; Zhou K; Xu S; Xu J; Yao H
    Bioorg Med Chem; 2022 Oct; 72():116977. PubMed ID: 36037626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells.
    Luo D; Yi Y; Peng K; Liu T; Yang J; Liu S; Zhao W; Qu X; Yu W; Gu Y; Wan S
    Eur J Med Chem; 2019 Sep; 178():365-379. PubMed ID: 31200238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria.
    Xu S; Luo S; Yao H; Cai H; Miao X; Wu F; Yang DH; Wu X; Xie W; Yao H; Chen ZS; Xu J
    J Med Chem; 2016 May; 59(10):5022-34. PubMed ID: 27089099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility.
    Ding C; Zhang Y; Chen H; Yang Z; Wild C; Chu L; Liu H; Shen Q; Zhou J
    J Med Chem; 2013 Jun; 56(12):5048-58. PubMed ID: 23746196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer.
    Yao H; Xie S; Ma X; Liu J; Wu H; Lin A; Yao H; Li D; Xu S; Yang DH; Chen ZS; Xu J
    J Med Chem; 2020 Aug; 63(15):8157-8178. PubMed ID: 32610904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents.
    Ke Y; Liang JJ; Hou RJ; Li MM; Zhao LF; Wang W; Liu Y; Xie H; Yang RH; Hu TX; Wang JY; Liu HM
    Eur J Med Chem; 2018 Sep; 157():1249-1263. PubMed ID: 30193221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Cytotoxicity Assessment of Novel 7-O- and 14-O-Derivatives of Glaucocalyxin A.
    Liu HC; Qiao LM; Zheng W; Xiang ZB; Chen HS; Yu SC; Zhang DZ; Wang T; Zhang YF; Jin YS
    Anticancer Agents Med Chem; 2020; 20(10):1241-1249. PubMed ID: 32116205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of 6,20-epoxy A-ring modified oridonin derivatives with antitumor activity through extrinsic and mitochondrial pathways.
    Li H; Luo X; Zhu F; Wang C; Wang J; Wang S; Hua H; Lu J; Li D
    Bioorg Chem; 2024 Oct; 151():107632. PubMed ID: 39003943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation.
    Hu X; Bai Z; Qiao J; Li H; Xu S; Wang X; Xu Y; Xu J; Hua H; Li D
    Eur J Med Chem; 2019 Jun; 171():169-179. PubMed ID: 30921757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation.
    Li D; Xu S; Cai H; Pei L; Zhang H; Wang L; Yao H; Wu X; Jiang J; Sun Y; Xu J
    Eur J Med Chem; 2013 Jun; 64():215-21. PubMed ID: 23644204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates.
    Xu J; Yang J; Ran Q; Wang L; Liu J; Wang Z; Wu X; Hua W; Yuan S; Zhang L; Shen M; Ding Y
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4741-4. PubMed ID: 18644718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.
    Li H; Gao X; Huang X; Wang X; Xu S; Uchita T; Gao M; Xu J; Hua H; Li D
    Eur J Med Chem; 2019 Sep; 178():446-457. PubMed ID: 31202992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents.
    Xu S; Yao H; Hu M; Li D; Zhu Z; Xie W; Yao H; Wu L; Chen ZS; Xu J
    J Nat Prod; 2017 Sep; 80(9):2391-2398. PubMed ID: 28901767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.